Cytisinicline
Cytisinicline is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Smoking cessation | D016540 | EFO_0004319 | 6 | 4 | 6 | 1 | 1 | 16 | |
| Tobacco use disorder | D014029 | F17 | — | — | 1 | 1 | — | 2 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 1 | — | — | 1 |
| Smoking | D012907 | EFO_0003768 | F17 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 | |
| Diet therapy | D004035 | — | 1 | — | — | — | 1 | ||
| Inflammation | D007249 | — | 1 | — | — | — | 1 | ||
| Exercise | D015444 | EFO_0000483 | — | 1 | — | — | — | 1 | |
| Vaping | D000072137 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CYTISINICLINE |
| INN | cytisinicline |
| Description | Cytisine is an organic heterotricyclic compound that is the toxic principle in Laburnum seeds and is found in many members of the Fabaceae (legume, pea or bean) family. An acetylcholine agonist, it is widely used throughout Eastern Europe as an aid to giving up smoking. It has a role as a nicotinic acetylcholine receptor agonist, a phytotoxin and a plant metabolite. It is an alkaloid, an organic heterotricyclic compound, a secondary amino compound, a lactam and a bridged compound. |
| Classification | Small molecule |
| Drug class | nicotinic acetylcholine receptor partial agonists/agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=c1cccc2n1C[C@@H]1CNC[C@H]2C1 |
Identifiers
| PDB | — |
| CAS-ID | 485-35-8 |
| RxCUI | 1723152 |
| ChEMBL ID | CHEMBL497939 |
| ChEBI ID | 4055 |
| PubChem CID | 10235 |
| DrugBank | DB09028 |
| UNII ID | 53S5U404NU (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more